Publications by authors named "W Czogala"
is a nosocomial pathogen that causes severe infections in immunocompromised patients. The aim of the study was to conduct a microbiological and clinical analysis of infections in children with malignancies or undergoing hematopoietic cell transplantation in Poland. We conducted a retrospective, multicenter study including children and adolescents under 19 years old treated between 2012 and 2021.
View Article and Find Full Text PDFWiskott-Aldrich syndrome (WAS) is a multifaceted monogenic disorder with a broad disease spectrum and variable disease severity and a variety of treatment options including allogeneic hematopoietic stem cell transplantation (HSCT) and gene therapy (GT). No reliable biomarker exists to predict disease course and outcome for individual patients. A total of 577 patients with a WAS variant from 26 countries and a median follow-up of 8.
View Article and Find Full Text PDFThe most common complications related to the treatment of childhood acute lymphoblastic leukemia (ALL) are infections. The aim of the study was to analyze the incidence and mortality rates among pediatric patients with ALL who were treated in 17 Polish pediatric hematology centers in 2020-2021 during the pandemic. Additionally, we compared these results with those of our previous study, which we conducted in the years 2012-2017.
View Article and Find Full Text PDFCharacteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia-Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022.
Cancers (Basel)
September 2023
Article Synopsis
- The FLT3 gene mutation occurs in 10-15% of pediatric acute myeloid leukemia (AML) cases and is linked to poorer outcomes in patients.
- A study analyzed data from 2005 to 2022, revealing that FLT3-ITD-positive patients had significantly lower survival rates compared to those without the mutation.
- Results indicated that treatment advancements, like FLT3 inhibitors and stem cell transplants, improved survival rates, while additional genetic mutations (WT1 and NPM1) impacted prognosis significantly.
Introduction: The aim of the study was to analyse the frequency of silent inactivation and allergic reaction to asparaginase (ASP) and its impact on treatment results in patients with lymphoblastic leukaemia.
Material And Methods: Seventy patients with acute lymphoblastic leukaemia treated with ASP were enrolled in the study. Asparaginase activity was monitored.